Professional Media briefs

Catherine DeAngelis will step down from her post as JAMA editor-in-chief next June, the journal said, and return to Johns Hopkins. During her 10-year career at the AMA-published medical publication, DeAngelis toughened conflict-of-interest guidelines, worked to require registration of clinical trials as a condition of publication and established the JAMA requirement that industry-sponsored clinical trials must have an independent academic statistician to review all data before a manuscript can be accepted and published. She was also criticized for letting some author conflicts go undisclosed.

A Columbia University study found that in 2007, 25 out of 32 consultants to medical device firms drawing $1 million-plus compensation failed to reveal those conflicts of interest in journal articles published the following year. The authors called for tougher disclosure policies at medical journals.

The FDA's Division of Drug Marketing, Advertising and Communication hit Baxter with a warning letter for a physician brochure for Aralast NP, expressing concern over “your continued violative promotion of your products” and citing two previous letters.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.